Vodobatinib

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameVodobatinib
Drug Alias NameSCO-088SCC-138K-0706SUN-K706SUNK-0706
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsParkinson DiseaseLewy Body DiseaseLeukemia, Myelogenous, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSlovakia +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSun Pharma Advanced Research Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSun Pharma Advanced Research Company LtdGeorgetown University
Inactive CompaniesN/A
Active IndicationsLewy Body DiseaseLeukemia, Myelogenous, Chronic
Inactive IndicationsParkinson DiseaseLeukemia, Myeloid

Other Information

ATC CodeN/A
Related LinksN/A